Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Induction of Paraptotic Cell Death in Breast Cancer Cells by a Novel Pyrazolo[3,4-h]quinoline Derivative through ROS Production and Endoplasmic Reticulum Stress
Phuong Linh Nguyen et al.
ANTIOXIDANTS (2022)
Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach
Shih-Chung Yen et al.
BIOORGANIC CHEMISTRY (2022)
EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia
David Taussig et al.
BLOOD (2022)
The Serine/Threonine Kinase HASPIN Is a Novel Dependency in t(8;21) AML
Mengdan Liu et al.
BLOOD (2022)
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Laura K. Schmalbrock et al.
BLOOD (2021)
3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo
Neetu Dayal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Anuhya Kommalapati et al.
CANCERS (2021)
CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells
Muhammad Usama Tariq et al.
BRITISH JOURNAL OF CANCER (2021)
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors
Ahmad S. Alotaibi et al.
BLOOD CANCER DISCOVERY (2021)
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
Sebastian Scholl et al.
CELLS (2020)
Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f] quinoline boronic acid ROCK inhibitors
Neetu Dayal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties
Clement Opoku-Temeng et al.
BIOORGANIC CHEMISTRY (2018)
Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor
Clement Opoku-Temeng et al.
CHEMICAL COMMUNICATIONS (2018)
Haspin: a promising target for the design of inhibitors as potent anticancer drugs
Nathalie Gisele Amoussou et al.
DRUG DISCOVERY TODAY (2018)
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
Neetu Dayal et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
Min Lin et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia
Wojciech Czardybon et al.
Oncotarget (2018)
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner
Remko Prevo et al.
CELL CYCLE (2018)
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Rhian M. Touyz et al.
NPJ PRECISION ONCOLOGY (2018)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Overcoming Myelosuppression Due to Synthetic Lethal Toxicity in FLT3-Targeted Acute Myeloid Leukemia Therapy
Alexander A. Warkentin et al.
ELIFE (2014)
MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia
Katherine A. Minson et al.
BLOOD (2014)
New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents
Katerina Gurova
FUTURE ONCOLOGY (2009)
Structure and functional characterization of the atypical human kinase haspin
Jeyanthy Eswaran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
SB1317, a potent and orally active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies
Kee C. Goh et al.
BLOOD (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
The role of fluorine in medicinal chemistry
Poonam Shah et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2007)
Share Paper
